Continuous Treatment Study of Topiramate in Migraine Participants

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of topiramate in participants with migraine (type of severe headache that occurs periodically and is often associated with nausea, vomiting and constipation or diarrhea) who completed the JNS019-JPN-02 study.

Clinical Trial Description

This is an open-label (all people know the identity of the intervention), multicenter (conducted in more than one center), dose-titration (dose escalation/reduction) study of topiramate in participants with migraine. This study is a continuous study for the participants who were enrolled in the JNS019-JPN-02 study. Participants who completed the JNS019-JPN-02 study will receive treatment for 52 weeks starting at Visit 4 of the JNS019-JPN-02 study. The present study will consist of 3 weeks of Transfer period (during this period the dose titration will take place and along with dose titration the new treatment will be initiated at 25 milligram per day [25mg/day]), Continuous treatment period (32 weeks), Exit period (up to 3 weeks) and Follow-up period (4 weeks). Participants in the Continuous treatment period will receive topiramate tablets orally in the dose range of 50 mg/day to 100 mg/day. Dose can be increased or decreased as per Investigator's discretion. The maximum daily dose will be 200 mg/day. Efficacy will be primarily evaluated by change from Baseline in the number of monthly migraine attacks in Continuous treatment period. Participants' safety will be monitored throughout the study. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01799590
Study type	Interventional
Source	Janssen Pharmaceutical K.K.
Contact
Status	Completed
Phase	Phase 2
Start date	August 2007
Completion date	November 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05525611` - Cabergoline as a Preventive Treatment for Chronic Migraine	N/A
Completed	`NCT06192173` - Patent Foramen Ovale Closure in Migraine
Recruiting	`NCT03832998` - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine	Phase 3
Enrolling by invitation	`NCT04196933` - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma	N/A
Not yet recruiting	`NCT06428838` - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context	Phase 3
Completed	`NCT06304675` - Manageable Environmental Factors in Migraine
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Recruiting	`NCT05517200` - Pilot Study for a Machine Learning Test for Migraine
Completed	`NCT04179474` - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine	Phase 1
Recruiting	`NCT04603976` - Registry for Migraine - Clinical Core	Phase 4
Completed	`NCT03597529` - CHOCOlate MeLatonin for AdolescenT MigrainE	Phase 2
Completed	`NCT04197349` - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman	Phase 1
Recruiting	`NCT05891808` - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting	`NCT05064371` - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan	Phase 3
Suspended	`NCT04069572` - Vibratory Stimulation for the Treatment of Chronic Pain	N/A
Not yet recruiting	`NCT04859374` - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach	N/A
Not yet recruiting	`NCT03083860` - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.	N/A
Completed	`NCT02905227` - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder	Phase 1
Enrolling by invitation	`NCT02532023` - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients	Phase 4
Completed	`NCT02108678` - One-Day Intervention for Depression and Impairment in Migraine Patients	N/A